Arialys Therapeutics, Inc. — Form D
Arialys Therapeutics, Inc. of LA JOLLA, CA, a company, filed a Form D exempt-offering notice with the SEC on 2022-12-02. The offering totals $55.0M, of which $14.3M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2022-12-02
- Form: D
- Accession: 0001921043-22-000005
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $55.0M
- Amount sold: $14.3M
- Remaining: $40.7M
- Investors: 6
- Date of first sale: 2022-11-18
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-466443
Issuer
- Name: Arialys Therapeutics, Inc.
- CIK: 0001956823
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2021
- Address: 11099 NORTH TORREY PINES ROAD, SUITE 290, LA JOLLA, CA, 92037
- Phone: 858-750-4700
Officers, directors & promoters (8)
| Name | Role | Location |
|---|
| Jay Lichter, Ph.D. | Executive Officer | La Jolla, CA |
| Tighe Reardon | Executive Officer | La Jolla, CA |
| Jay Lichter, Ph.D. | Director | La Jolla, CA |
| Peter Flynn, Ph.D. | Director | San Diego, CA |
| Peter Flynn, Ph.D. | Executive Officer | San Diego, CA |
| Brian Slingsby, M.D., Ph.D., M.P.H. | Director | La Jolla, CA |
| Ed Hurwitz | Director | San Diego, CA |
| Ashish Xavier, Ph.D. | Director | San Diego, CA |
Other filings by this issuer (1)
More